Is TECX or TSHA more undervalued in 2026?

CirclFi compares Tectonic Therapeutic, Inc. (TECX) and Taysha Gene Therapies, Inc. (TSHA) using 13 institutional-grade valuation models. TECX has a Quality of Company score of 4.3/10 while TSHA scores 6.0/10.

Which is a better buy — TECX or TSHA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TECX and TSHA valuations compare?

TECX at $31.16 and TSHA at $5.87 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TECX vs TSHA Valuation Comparison 2026 — Intrinsic Value Analysis

TECX

Biological Products, (No Diagnostic Substances)

Tectonic Therapeutic, Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$31.16

Last close

Models

7/13

Active

TSHA

Biological Products, (No Diagnostic Substances)

Taysha Gene Therapies, Inc.

Quality

6.0

out of 10

Value Trap

SAFE

Price

$5.87

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	TECX Fair Value	TECX Upside	TSHA Fair Value	TSHA Upside
Bayesian DCF	Intrinsic	$14.60	-53.2%	$1.90	-67.6%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$18.11	-41.9%	$1.05	-82.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TECX vs TSHA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TECX vs TSHA — Which Stock Is More Undervalued?

TSHA scores higher with a 6.0/10 quality rating vs TECX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Tectonic Therapeutic, Inc. (TECX) and Taysha Gene Therapies, Inc. (TSHA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TECX currently trades at $31.16 with a QOC of 4.3/10, while TSHA trades at $5.87 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).